Strong Companies the Market Marked Down

The Setup

The first three installments of The Five each led with a single platform metric. The dividend list filtered by Moat score. The Wall Street disconnect list filtered by the gap between analyst targets and platform data. The balance sheet list filtered by Financial Health. This week the filter is the combination that Wealth Engine Pro's research treats as the strongest setup of all: a company rated Elite or Strong on Company Strength, trading below its calculated Fair Value, and carrying a Bullish forward Outlook. Strong fundamentals, a discounted price, and a positive forward signal, all at once.

We started with every company the platform rates Elite or Strong, filtered to those flagged Undervalued with market capitalizations above $5 billion, and kept only the names with a Bullish Outlook. That screen returned 23 companies. From those, we selected five that span different sectors and different reasons for being cheap: a biopharma giant buried under acquisition charges, an oil producer the market left behind, an IT services leader caught in the AI-disruption dragnet, a software company written off as dead, and a specialty insurer nobody talks about. The screen does the objective work. The selection adds sector diversity and avoids stacking the list with names we have already covered at length.

Gilead Sciences (GILD)

Gilead Sciences (GILD) earns a Company Strength score of 70 (Strong), with Financial Health of 80/100, a Moat of 9/15, and a Growth score of 12/15. The platform calculates Fair Value at $160.69 and assigns a Bullish outlook, which puts the recent price near $129 roughly 25% below the systematic estimate. For a company this size and this profitable, a 25% discount is unusual. The reason it exists has almost nothing to do with the business and almost everything to do with accounting.

Gilead beat in the first quarter of 2026, with revenue up 4.4% to $6.96 billion and management raising full-year revenue guidance to roughly $30.2 billion. The HIV franchise, more than half of revenue, grew 10%, with Biktarvy holding over 52% of the U.S. treatment market and the PrEP prevention business up 87% year over year. Oncology contributed too: Trodelvy sales rose 37%. Adjusted operating margins run near 47%. None of that is the story the stock price is telling.

The stock sits about 17% below its 52-week high because Gilead is running the most active acquisition year in its history, and roughly $11.5 billion in one-time charges tied to deals like the $7.8 billion Arcellx purchase land on the income statement all at once, producing a reported loss for the year on a GAAP basis. Those charges are real cash spent, but they are non-recurring, and they obscure a base business growing 5% to 6% with no major patent expirations until 2036. The market is reacting to a headline loss. The platform is scoring the franchise underneath it. That gap is the entire thesis.

EOG Resources (EOG)

EOG Resources (EOG) scores 73 (Strong) on Company Strength, with Financial Health of 72/100, a Moat of 11/15, and a Growth score of 13/15, the highest growth mark of the five. Fair Value is calculated at $182.99 with a Bullish outlook. With the stock dragged into the high $110s by the recent pullback in oil, that is roughly 29% below the platform's estimate. EOG is the clearest case on this list of a strong company being repriced by something outside its control.

The first quarter of 2026 was a beat. EOG generated $1.8 billion in adjusted net income and $1.5 billion in free cash flow, returned nearly $950 million to shareholders through dividends and buybacks, and reaffirmed a 2026 free cash flow target of roughly $8.5 billion, a record, with a commitment to return at least 70% of it. The balance sheet breakeven sits below $50 WTI. After-tax rates of return on its core wells exceed 100% at $55 oil. The recently integrated Encino assets in the Utica hit their $150 million synergy target in under a year.

So why is it cheap? Energy is out of favor, natural gas is soft, and crude has pulled back from its spring highs as markets weigh a potential de-escalation in the Gulf. The same forces we examined in Oil at $100 cut both ways, and right now they are cutting against the price. But the platform is not scoring the spot price of crude. It is scoring a low-cost, oil-weighted producer with a fortress balance sheet built to generate cash and return it across the cycle, including at oil prices well below today's. The market is selling the commodity. The data is scoring the operator.

Infosys (INFY)

Infosys (INFY) carries a Company Strength of 74 (Strong) and the highest Financial Health score of the five at 88/100, with a Moat of 12/15. Its Growth score is the lowest of the group at 8/15, and that is the honest tension in this pick. Fair Value is calculated at $16.11 with a Bullish outlook, putting the ADR near $13 roughly 29% below the estimate. Infosys is cheap because the entire IT services sector is under a cloud, and the cloud has a name: artificial intelligence.

The fundamentals are those of a fortress, not a casualty. For the fiscal year ended March 2026, Infosys grew revenue 3.1% in constant currency while holding operating margins near 21%, and it returned more than $4 billion to shareholders through its largest-ever buyback and a dividend raised 11.6%. Large deal signings rose 28%, with net-new work making up 55% of the full-year total. Infosys is now the strategic AI partner for 18 of its top 20 financial services clients, built on its Topaz and Cobalt platforms.

The bear case is not imaginary, and we said as much when we flagged Snowflake as a stock the data could not support. The fear is that agentic AI compresses the price of the routine work that built the offshore services model, and Infosys itself guides to only 1.5% to 3.5% revenue growth in constant currency for fiscal 2027. That is why this is a quality-and-value name rather than a growth story. The difference from Snowflake is which side of the disruption the data puts the company on. There, the platform rated a Weak, Bearish business priced for perfection. Here it rates a Strong, Bullish franchise with an 88 Health score, repositioning client by client around the very technology the market fears, and trading at a discount as if the transition has already failed.

Zoom Communications (ZM)

Zoom Communications (ZM) is the only Elite-rated name on this list, with a Company Strength of 84, a Moat of 14/15, Financial Health of 80/100, and a Growth score of 12/15. Fair Value is $135.65 with a Bullish outlook, putting the recent price near $110 about 21% below the estimate. The narrative on Zoom is that it was a pandemic stock whose moment passed. The data describes a cash machine the market stopped paying attention to.

In the first quarter of fiscal 2027, reported in late May, Zoom posted its fastest revenue growth in nearly three years, up 5.5% to about $1.24 billion, led by 7.2% enterprise growth. Adjusted earnings of $1.55 per share beat estimates, and management raised full-year guidance to $5.96 to $6.00 in EPS on roughly $5.08 billion in revenue, both above Wall Street's expectations. The profitability is the headline: non-GAAP gross margins near 80%, operating margins around 40%, nearly $7.8 billion in cash and investments, and a fresh $1 billion buyback authorization. Zoom Phone passed 10 million paid seats.

The contrast with the Snowflake story matters here too. Where some software companies face AI as a threat, Zoom is monetizing it: AI Companion usage grew more than four times year over year, and the company is layering paid AI features and contact-center tools on top of an installed base it already owns. The market priced Zoom as a melting ice cube. The first quarter showed acceleration, not decline, and the balance sheet means Zoom can repurchase stock and fund AI development without borrowing a dollar. As we argued in our look at the AI race, the companies that win are the ones turning AI into product, not the ones it disrupts. A no-growth narrative attached to a re-accelerating, 40%-margin business is exactly the disconnect this list exists to surface.

Kinsale Capital (KNSL)

Kinsale Capital (KNSL) is the name on this list most readers will not recognize, and that is the point. The specialty insurer earns a Company Strength of 77 (Strong), a Moat of 12/15, Financial Health of 73/100, and a Growth score of 13/15. Fair Value is $354.12 with a Bullish outlook, and the stock recently traded near $305, close to its 52-week low and roughly 22% below the platform estimate. There is no narrative on Kinsale. There is just a quietly excellent business the market has cooled on.

Kinsale writes excess and surplus lines insurance, the hard-to-place risks that standard carriers will not touch, and it does so with discipline that shows up in the numbers. In the first quarter of 2026, operating earnings per share rose 37.7%, net income climbed 26% to $112.6 million, and the company posted a combined ratio of 77.4%. In property and casualty insurance, anything below 100% means underwriting is profitable before investment income; a ratio under 80% is elite, and Kinsale runs there consistently. Annualized operating return on equity was 24%, and net investment income grew 26.5%. The stock trades at roughly 13.5 times earnings, near the low end of its history.

So what cooled the market? Growth has decelerated from its torrid pace. Gross written premium dipped 0.5% in the quarter, and E&S pricing has softened as more capacity enters the market. Investors who paid up for hypergrowth are repricing the stock for a slower one. But decelerating from extraordinary growth to merely strong growth is not the same as deterioration, and a 24% return on equity with a sub-78% combined ratio is not a company in trouble. The platform is scoring the underwriting engine and the balance sheet. The market is reacting to a slowdown in the growth rate. For a list about strong companies trading at a discount, that is the definition of the assignment.

What the Wealth Engine Scores Say

Here is what the platform's systematic scoring shows for all five stocks right now.

Every stock on this list shows the same three-part pattern: Strong or Elite Company Strength, an Undervalued Fair Value designation, and a Bullish forward Outlook. That combination is rare. It is also the opposite of what we found in The Five: Stocks Wall Street Loves, where five Weak, Bearish companies traded far above fair value. Here the systematic scores and the editorial thesis agree: these are good businesses on sale.

These scores are systematic. They evaluate companies on reported financials, balance sheet quality, moat characteristics, and valuation models including discounted cash flow, peer comparison, and earnings power. They measure what a company is today, not what it might become. That is by design: the scoring keeps emotion and forward speculation out of the numbers.

What this article adds is the why. Each of these five is discounted for a specific, identifiable reason: acquisition charges at Gilead, a falling oil price at EOG, AI-disruption fear at Infosys, a stale pandemic narrative at Zoom, and a growth deceleration at Kinsale. In every case the platform is scoring the durable business underneath the temporary reason for the discount. When strong fundamentals, a below-fair-value price, and a Bullish outlook line up at once, that is the strongest setup the data produces. Research any of these names yourself on the platform and decide whether the discount is a warning or an opportunity.

What Didn't Make the List

PTC (PTC) and Deckers (DECK) both cleared the same screen, and both are Strong, Bullish, and trading below fair value. They are absent here for a simple reason: we made the full case for each on its own. The argument for PTC's industrial software backbone and the argument for Deckers and HOKA's runway run far longer than a single entry on a list of five. Stacking them here would have been a repeat rather than a discovery.

A cluster of precious-metals miners also cleared the screen, including Iamgold (IAG), SSR Mining (SSRM), AngloGold Ashanti (AU), and Buenaventura (BVN), each rated Strong with Undervalued, Bullish profiles. That is interesting enough to deserve its own treatment rather than a single slot, and concentrating this list in one sector would have undercut the diversification that makes it useful. The gold names are banked for a future edition.

Regeneron (REGN) was one of the cheapest names in the entire screen, trading roughly 29% below fair value with a Strong Company Strength. It missed the final five on the third leg of the test: its forward Outlook is Neutral, not Bullish. For a list built specifically on the alignment of strong fundamentals, a discounted price, and a positive forward signal, two out of three was not enough.

What Could Go Wrong

The common thread that makes these stocks cheap is also the common risk: every one of them is undervalued against a model estimate, and a model is only as good as its assumptions. Fair Value is calculated from discounted cash flow, peer multiples, and earnings power. If normalized earnings turn out lower than the models assume, the discount is smaller than it looks. That caution applies most to Gilead, whose 2026 GAAP picture is distorted by one-time charges, and to EOG, whose cash flows swing with a commodity price no one controls.

Each name also carries its own specific risk. Gilead's near-term catalysts are binary: a negative regulatory decision on its CAR-T therapy or a disappointing late-stage oncology readout would remove a key part of the story. EOG is a bet on oil staying high enough; if crude keeps falling, the record free cash flow target compresses with it. Infosys faces the genuine possibility that AI deflates IT-services pricing faster than it can win transformation work, which would turn slow growth into no growth. Zoom's re-acceleration is off a low base, and management has flagged longer enterprise sales cycles; if that growth stalls, the stock is a no-growth cash machine again. Kinsale's softening pricing and decelerating premiums could pressure the combined ratio, and the company carries an active legal matter and recent insider selling that bear watching.

Undervalued is not the same as guaranteed. A stock can trade below fair value for longer than expected, and a cheap strong company can stay cheap if the market's reason for discounting it turns out to be right rather than overblown. The thesis on each of these five is that the reason for the discount is temporary and the business underneath is durable. That is a judgment, and the data supports it, but it is not a certainty. The platform gives you the scores. The decision is yours.

The Bottom Line

Four weeks of The Five have now approached the same question from four directions. The dividend list filtered by Moat and found payouts protected by real competitive advantage. The Wall Street disconnect list filtered by the gap between narrative and data and found premiums with nothing behind them. The balance sheet list filtered by Financial Health and found fortresses. This week we asked the platform for the full trifecta at once: strong, cheap, and pointed in the right direction.

Gilead, EOG, Infosys, Zoom, and Kinsale share that profile. All five are rated Elite or Strong. All five trade below the platform's Fair Value. All five carry Bullish outlooks. And each one is discounted for a reason that has more to do with a headline, a commodity, or a stale narrative than with the durability of the business. That is the setup Wealth Engine Pro's research treats as the strongest of all, because it is the rare case where quality and price agree.

That is the Wealth Engine Pro approach: start with the numbers, apply a systematic filter, and let the data surface what deserves attention. No predictions about where the market goes next. No speculation about the macro. Just Company Strength, Fair Value, and Outlook, scored systematically, pointing at five companies the market has marked down for reasons the data looks past. Look them up on the platform. The scores speak for themselves.